Eris Lifesciences Expands Global Reach with ANVISA Approval for Ahmedabad Facility

In a significant strategic move, Eris Lifesciences announced that a manufacturing unit at its Ahmedabad campus has received approval from ANVISA, Brazil’s national health regulatory agency. This approval, which follows a successful inspection in May 2025, marks a major milestone as it enables the company to enter Brazil, the largest and most promising pharmaceutical market in South America.

A Stamp of Quality and Global Ambition

A company spokesperson highlighted the importance of this approval, stating it serves as a “tangible endorsement” of the company’s commitment to Good Manufacturing Practices (GMP) and high-quality systems. The Ahmedabad facility’s successful inspection by a stringent regulatory authority like ANVISA builds on its record of passing inspections from various other regulatory agencies earlier in the year. This consistent regulatory compliance underpins Eris’s strategy to expand its global footprint beyond its dominant position in the Indian market.

For Eris, which has invested approximately INR 4,000 crore over the last three years to diversify its operations across geographies, technologies, and therapeutic areas, the ANVISA approval is a direct result of this forward-looking investment strategy.

A Powerhouse in Indian Branded Formulations

Established in 2007, Eris Lifesciences has quickly risen to become one of the top 20 pharmaceutical companies in India. The company has an annual branded formulations revenue exceeding INR 3,000 crore, according to AWACS. Eris has built a strong and diversified portfolio in high-growth specialties and super-specialties, including Diabetes, Cardiovascular, Dermatology, Neurology, and Critical Care, among others.

Eris operates six manufacturing facilities, producing a wide range of prescription products in various dosage forms, from oral solids and liquids to sterile injectables and biologics. Its extensive network of approximately 5,000 stockists and over 500,000 retail pharmacies across India solidifies its domestic market leadership.

The company’s financial performance has been robust, with a 2.6x growth in revenue and operating profit over the last five years, reaching a revenue of INR 2,894 crore in FY25. The ANVISA approval is expected to further fuel this growth by providing access to a new, high-potential international market.